Immunovant, Inc.
IMVT
$25.75
$0.110.43%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -464.20M | -464.69M | -447.30M | -413.84M | -382.71M |
| Total Depreciation and Amortization | 422.00K | 420.00K | 404.00K | 377.00K | 332.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 56.37M | 55.30M | 54.63M | 49.62M | 47.84M |
| Change in Net Operating Assets | -15.48M | -21.99M | -24.82M | -12.03M | 9.60M |
| Cash from Operations | -422.89M | -430.95M | -417.09M | -375.87M | -324.94M |
| Capital Expenditure | -201.00K | -381.00K | -577.00K | -759.00K | -708.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -201.00K | -381.00K | -577.00K | -759.00K | -708.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.04B | 480.91M | 457.04M | 454.81M | 5.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -905.00K | -319.00K | -319.00K | -319.00K | 0.00 |
| Cash from Financing | 1.04B | 480.59M | 456.72M | 454.49M | 5.43M |
| Foreign Exchange rate Adjustments | 201.00K | -325.00K | -154.00K | 747.00K | 3.97M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 619.84M | 48.93M | 38.91M | 78.61M | -316.25M |